Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...

Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of limb-girdle muscular dystrophy (LGMD), a group of rare genetic disorders marked ...

Wells Fargo initiated coverage of Sarepta (SRPT) with an Overweight rating and $115 price target Despite the recent Gr5 AE case, the firm ...

The death of a patient treated with Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys has played havoc with its share price – although analysts believe that its benefits still ...

Zhu highlighted that ELEVIDYS is still considered the best treatment option for most young DMD patients, and the commercial opportunity for Sarepta remains substantial. Wells Fargo does not anticipate ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( is currently investigating potential violations of the federal ...

Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Sarepta (SRPT) to $182 from $196 and keeps an Overweight rating on the ...

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene therapy Elevidys in the wake of the death of a patient who received the ...

AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common ...